Jasper Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jasper Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($71.27M) | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | ($64.47M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($37.69M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($30.64M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($31.67M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($596.4K) | May 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($76.24M) | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | ($68.86M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($51.20M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($36.83M) | Mar 8, 2023 |
| FY2023 | Sep 24, 2021 | $2.90M | Mar 5, 2024 |
| FY2021 | Dec 31, 2020 | ($20.68M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($136.3K) | May 24, 2021 |
| FY2023 | Nov 21, 2019 | $2.90M | Mar 5, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $79.90M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $94.89M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $48.36M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $93.65M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $23.36M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $101.69M | May 24, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $18.23M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $16.45M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $12.37M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $24.14M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $14.65M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $10.85M | May 24, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $61.67M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $78.44M | Feb 28, 2025 |
| FY2024 | Dec 31, 2022 | $35.99M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $69.52M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($35.13M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($4.73M) | Mar 18, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (4) | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | (6) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (4) | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | (6) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 8, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $71.64M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $86.89M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $38.25M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $84.70M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $19.84M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | May 24, 2021 |